The presence of HPV DNA in breast cancer
More details
Hide details
Departament of Virology, Medical University of Lublin, Poland
Departament of Oncology, Medical University of Lublin, Poland
Departament of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland
Paweł Macieląg   

Departament of Virology, Medical University of Lublin, Chodźki 1, 20‑093 Lublin, Poland
J Pre Clin Clin Res. 2013;7(2):86–89
Introduction and objective:
For many years the incidence of breast cancer remained at a high level. There are many risk factors which increase the probability of occurrence of the development of neoplastic transformation. Human papillomavirus has oncogenic properties and many studies have demonstrated its role in malignant transformation of cervical epithelial. These properties seems to be of great importance also in the formation of cancers in different organs.

This study aims to assess the prevalence of HPV genetic material in women with breast cancer, and compare the prevalence of HPV DNA with a control group of women with non-malignant changes in the breast.

Material and Methods:
The biological material to be examined, obtained from 60 patients with breast cancer treated in Centrum Onkologii Ziemi Lubelskiej in Lublin, was fixed in paraffin blocks. The control group consisted of 30 patients with suspected tumour growth; however, the histopathological examination ruled out breast cancer cells. HPV DNA isolation was performed using a DNA Mini-Kit (Qiagen). Amplification and genotyping was carried out using a set of INNO-LIPA HPV Genotyping (Innogenetics) according to the manufacturer’s instructions.

The genetic material of the virus was detected in 8 women with breast cancer. DNA of HPV was not found in samples from the control group. HPV 16 occurred in 50%.

HPV genetic material is present in breast cancer cells. HPV is absent in women with benign breast changes. A positive correlation was found between the presence of the HPV genome and the age of the women: the virus is more common in women aged > 60 years, also noted was the presence of HPV associated with the type of histopathological diagnosis. HPV is significantly more frequent in invasive lobular cancer.

Raporty na podstawie danych Centrum Onkologii (access: 2013.08.01) (in Polish).
Didkowska J, Wojciechowska U, Zatoński W. Prognozy zachorowalności i umieralności na nowotwory złośliwe w Polsce do 2025 roku. Centrum Onkologii Instytut. Warszawa 2009 (in Polish).
Schmidt C. The Breast Cancer Chemoprevention Debate. J Natl Cancer Inst. 2011; 103(22): 1646–1647.
Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 2012; 134(2): 875–880.
Krzakowski M et al. (eds.). Zalecenia postępowania diagnostycznoterapeutycznego w nowotworach złośliwych. Via Medica, Gdańsk 201.
Szewczyk K. Epidemiologia i profilaktyka raka piersi. In: Kornafel J (eds.). Rak piersi. CMKP, Warszawa 2011.
Zandberg D P, Bhargava R, Badin S, Cullen, K. J. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin. 2013; 63(1): 57–81.
Gogilashvili K, Shonia N, Burkadze G. The role of human papillomavirus in oral sqamous cell carcinoma (review). Georgian Med News. 2012; 213: 32–36.
Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science 2006; 110: 525–541.
Sotlar K, Diemer D, Stubner A, Menton S, Menton M, Dietz K, et al. Detection of high-risk human papillomavirus (HPV) E6 and E7 oncogene transcripts increases the specificity of the detection of a cervical intraepithelial neoplasia (CIN) Verh Dtsch Ges Pathol. 2005; 89: 195–200.
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004; 324(1): 17–27.
Evans M, Adamson C, Papillo J, St John TL, Leiman G, K Cooper. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer. 2006; 106(5): 1054–1064.
Lizano M, Berumen J, García-Carrancá A. HPV-related carcinogenesis: basic concepts, viral types and variants. Arch Med Res. 2009; 40(6): 428–434.
Bosch F X, QiaoY-L, Castellsagué X The epidemiology of human papillomavirus infection and its association with cervical cancer International Journal of Gynecology and Obstetrics 2006; 94: 8–21.
Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010;117(2): 5–10.
Szostek S, Klimek M, Zawilinska B, Kosz-Vnenchak M. Genotypespecific human papillomavirus detection in cervical smears. Acta Biochim Pol. 2008; 55(4): 687–692.
Micalessi IM, Boulet GA, Bogers JJ, Benoy IH, Depuydt CE. Highthroughput detection, genotyping and quantification of the human papillomavirus using real-time PCR. Clin Chem Lab Med. 2011; 50(4): 655–661.
Hubbard RA. Human papillomavirus testing methods. Arch Pathol Lab Med. 2003; 127(8): 940–945.
Mou X, Chen L, Liu F, Shen Y, Wang H, Li Y, Yuan L, et al. Low prevalence of human papillomavirus (HPV) in Chinese patients with breast cancer. J Int Med Res. 2011; 39(5): 1636–1644.
Hedau S, Kumar U, Hussain S, Shukla S, Pande S, et al. Breast cancer and human papillomavirus infection: no evidence of HPV etiology of breast cancer in Indian women. BMC Cancer. 2011; 11:27.
Lawson JS, Glenn WK, Heng B, Ye Y, Tran B, et al. Koilocytes indicate a role for human papilloma virus in breast cancer. Br J Cancer. 2009; 101(8): 1351–1356.
Simoes PW, Medeiros LR, Simoes Pires PD, Edelweiss MI, Rosa DD, et al. Prevalence of human papillomavirus in breast cancer: a systematic review. Int J Gynecol Cancer. 2012; 22(3): 343–347.
Frega A, Lorenzon L, Bononi M, De Cesare A, Ciardi A, et al. Evaluation of E6 and E7 mRNA expression in HPV DNA positive breast cancer. Eur J Gynaecol Oncol. 2012; 33(2): 164–167.